Skip to Content

'
Anne S. Tsao, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Mesothelioma Program, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Thoracic Chemo-Radiation Program, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 432
Houston, TX 77030
Room Number: Faculty Center FC9.3002
Phone: 713-792-6363
Fax: 713-792-1220

Education & Training

N/A

Experience/Service

Academic Appointments

Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002-5/2010

Administrative Appointments/Responsibilities

Chair, Clinical Research Committee (CRC), The University of Texas MD Anderson Cancer Center, Houston, TX, 2010-2013
Associate Member, Institutional Review Board (IRB), The University of Texas MD Anderson Cancer Center, Houston, TX, 2010-2013

Other Appointments/Responsibilities

Coordinator Clinical Protocol, University of Chicago, Dept of Rheumatology, Chicago, IL, 1997-1999

Institutional Committee Activities

Chair, MDACC Clinical Research Committee (CRC), 2010-2013
Member, MDACC Clinical Research Committee (CRC), 6/2008-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Sejpal S, Komaki R, Tsao A, Chang JY, Liao Z, Wei X, Allen PK, Lu C, Gillin M, Cox JD. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer 117(13):3004-13, 7/2011. e-Pub 1/2011. PMID: 21264827.
2. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The Battle Trial: Personalizing Therapy for Lung Cancer. Cancer Discovery 1(1):44-53, 6/2011.
3. Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, Gillin M, Mohan R, Cox JD. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. e-Pub 3/22/2011. PMCID: PMC3174272.
4. Tsao AS, Garland L, Redman M, Kernstine K, Gandara D, Marom EM. A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. J Thorac Oncol 6(3):598-601, 3/2011. PMID: 21270668.
5. Garland L, Chansky K, Wozniak A, Tsao, Gadgeel S, Verschraegen C, DaSilva M, Redman M, Gandara D. Phase II Study of AZD2171 in patients with malignant pleural mesothelioma SWOG 0509. J Thoracic Oncol 6(11):1938-45, 2011.
6. Garland L, Flores R, Tsao A. Individualizing mesothelioma treatment: small steps into a brighter future. Clin Lung Cancer 11(6):371-3, 11/2010. PMID: 21062727.
7. Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, Roder J, Tsypin M, Herbst RS, Tsao AS, Tran HT, Dang TP. VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 69(3):337-40, 9/2010. e-Pub 12/2009. PMCID: PMC2891357.
8. Tsao AS, Roth J, Herbst R. Future directions in multimodality therapy for III A NSCLC: Intergroup Trial 0139. Nature Reviews Clinical Oncology 7(1):10-12, 1/2010. PMID: 20029443.
9. Dayyani F, Etzel C, Liu M, Ho Chung-Han, Lippman S, Tsao A. Meta-anlysis of the impact of human papilomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head and Neck Oncology 2(15), 2010.
10. Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM, Hong WK, Papadimitrakopoulou V. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) 2(11):931-941, 11/2009. PMID: 19892663.
11. McAleer MF, Tsao AS, Liao Z. Radiotherapy in malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 75(2):326-37, 10/2009. PMID: 19735859.
12. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant Pleural Mesothelioma. J Clin Oncol 27(12):2081-90, 4/2009. e-Pub 3/2009. PMID: 19255316.
13. Ivanova AV, Ivanov SV, Prudkin L, Nonaka D, Liu Z, Tsao A, Wistuba I, Roth J, Pass HI. Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. Mol Cancer 8:91, 2009. e-Pub 10/2009. PMCID: PMC2776015.
14. Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 6(7):1962-1970, 7/2007. PMID: 17620427.
15. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 7(5):326-331, 3/2006. PMID: 16640804.
16. Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, Spitz M, Hong WK, Gazdar A, Wistuba I. Clinical-Pathological Characteristics of the EGFR Gene Mutation in Non-small Cell Lung Cancer. J Thorac Oncol 1(3):231-239, 3/2006. PMID: 17409862.

Grant & Contract Support

Title: PRMRP
Funding Source: Department of Defense (DOD)
Role: Principal Investigator
Duration: 2010 - 2014
 
Title: National Institute of Health K12 Clinician Investigator Award
Funding Source: NIH/NCI
Role: Recipient
Duration: 2004 - 2008
 
Title: Young Investigator Award
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 2003 - 2005

Last updated: 12/19/2012